Research - Aspen

Publications

A Report from a Workshop of the International Stem Cell Banking Initiative, Held in Collaboration of Global Alliance for Ipsc Therapies and the Harvard Stem Cell Institute, Boston, 2017. (Stem Cells. 2019 Sep;37(9):1130-1135. doi: 10.1002/stem.3003. Epub 2019 Aug 6.)

Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat Parkinson’s Disease. (Stem Cells And Development. Volume 27, Number 14, 2018. DOI: 10.1089/scd.2018.0107)

Whole-Genome Mutational Burden Analysis of Three Pluripotency Induction Methods. (Nat Commun. 2016 Feb 19;7:10536. doi: 10.1038/ncomms10536.)

Increased Risk of Genetic and Epigenetic Instability in Human Embryonic Stem Cells Associated with Specific Culture Conditions. (PLoS One. 2015 Feb 25;10(2):e0118307. doi: 10.1371/journal.pone.0118307. eCollection 2015.)

A Bioinformatic Assay for Pluripotency in Human Cells. (Nat Methods. 2011 April; 8(4): 315–317. doi:10.1038/nmeth.1580.)

Regulatory Networks Define Phenotypic Classes of Human Stem Cell Lines. (Nature. 2008 Sep 18;455(7211):401-5. doi: 10.1038/nature07213. Epub 2008 Aug 24.)

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.